Status: Recruiting
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.
Participants needed: 32
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: AnHorn Medicines Co. Ltd.Updated: Jul 13, 2026Locations: 1
Eligibility criteria
Age range: 18 to 65 years. [+3]
A history of any clinically serious illness, such as circulatory system, endocri... [+19]